	1	
•	٠	-
	ı	

, 1	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	\	for form 1449	A/PTO	Complete If Known			
2	7 2004 R	IN S	TATEME	TION DISCLOSURE NT BY APPLICANT uny sheets as necessary)	Application Number	10/691,928		
			•	•	Filing Date	October 23, 2003	_	
•					First Named Inventor	Jay A. Goldstein	_	
					Group Art Unit	1616	_	
					Examiner Name			

			U.S. PATENT DOCUM	IENTS			
Examiner Initials*	Cite No. ¹			US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code (if know					
/NWS/		4,912,124	Das, et al.	03-27-1990			
		5,002,938	Wang, et al.	03-26-1991			
		5,021,458	Maeda, et al.	06-04-1991	\		
		5,110,809	Wang, et al.	05-05-1992	·		
		5,174,475	Day, et al.	12-29-1992			
		5,219,877	Shah, et al.	06-15-1993			
		5,310,545	Eisen	05-10-1994			
		5,407,663	Eisen	04-18-1995			
_		6,075,056	Quigley, Jr., et al.	06-13-2000	·		
/NWS/		6,080,744	Ayon-Covarrubias	06-27-2000			

				F	OREIGN PATENT DOCUMEN	ΠS		
Examiner Cite Initials* No.1			Foreign Patent Docu	ument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear	Te
		Office.3	Number ⁴	Kind Code ⁵ (if known)				

Examine Signature	/Nathan Schlientz/	Date Considered	08/02/2007

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant to place a check mark here if English language Translation is attached.

	•	
_		ı
•		-

6 F		Substitute for			c a collection of information unless it contains a valid OMB control number Complete if Known			
FEB 2	7 2004 AD-2400	STATE	MENT	N DISCLOSURE BY APPLICANT	Application Number	10/691,928		
Į		•	•		Filing Date	October 23, 2003		
					First Named Inventor	Jay A. Goldstein		
					Group Art Unit	1616		
ŀ					Examiner Name			
S	Sheet	2	of .	2	Attorney Docket Number	JAG 100		

		OTHER ART NON PATENT LITERATURE DOCUMENTS	_
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
/NWS/		ADAMS, et al., "Perianal ulcerations from topical steroid use," Cutis 69(1): 67-68 (2002).	
		BARSKY, "Clinical comparison of desonide cream with fluocinonide cream in steroid-responsive dermatologic disorders," Cutis 18(6): 826-30 (1976).	
		FLEMING, et al., "An inflammatory eruption associated with recombinant human IL-6," <i>Brit. J. Dermatol.</i> 130(4): 534-40 (1994).	
		GREENBERG, et al., "Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections," <i>Pediatr. Dermatol.</i> 19(1): 78-81 (2002).	•
		JORIZZO, et al., "Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients," <i>J. Am. Acad. Dermatol.</i> 33(1): 74-7 (1995).	
V		LUCKY, et al., "Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis," <i>Cutis</i> 59(3): 151-153 (1997).	
/NWS/		WEINSTEIN & BERMAN, "Topical treatment of common superficial tinea infections," Am. Fam. Physician 65(10): 2095-2102 (2002).	_

		,		
Examiner's	Mathen Cabliants/		Date Considered	00/00/0007
Signature	/Nathan Schlientz/			08/02/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Sheet

JAG 100

· · · · · · · · · · · · · · · · · · ·	ratent	BIT (1806) BIX OINCE. U.S. DEL ANTINETT OF COMMENCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collec-	tion of information unless it contains a valid OM	B control number
Substitute for form 1449A/PTO	Co	emplete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/691,928
(use as many sheets as necessary)		
	Filing Date	October 23, 2003
RADEMAN	First Named Inventor	Jay Goldstein
	Group Art Unit	1616
	Examiner Name	

Attorney Docket Number

U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS Detail Cited Process Columns Lines Where Relevant										
Examiner Initials*	Cite No. ¹	Number Kind Code ²		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
			(if known)							
/NWS/I		4,895,72	27	Allen	01-23-1990					
		<u> </u>								
					_					
					-					
			- -							
		 								
						<u> </u>				
		ļ			_					
		 								
		 								
		+								

				F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1				Applicant of Cited Document Mind Cited Document M	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office.3	Number ⁴	Kind Code ⁵ (if known)				
							•	↓
		 		·				+
		 						+-
		 						
					· · · · · · · · · · · · · · · · · · ·			lacksquare
		 				 -		┼
	├	 -		_				+
_	 							
								<u> </u>
		7.1-71	A 1 1					

Examiner's Signature	/Nathan Schlientz/	Date Considered	08/02/2007	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

					٠.	
Sease bee	2000	rien i	a) inci	to Price	: h.v.s	

39	(C)\$8.08A	(10.9)
Approved for use through 10/31/99	CMS COS	1.003
Patent and Trademark Office: U.S. DEPARTMEN	OF COM	ERC.

Under the Properties Resturben Act of 1995, no parsons are required to respond to a consention of information of Substitute for form 1449A/PTO		plete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/691,928	•
facel partition (Variation and Indianastics).	Filing Date	October 23, 2003	
	First Named Inventor	Jay A. Goldstein	
	Group Art Unit	1616	~~~
	Examiner Name	Nathan W. Schlientz	****
Sheet 1 of 1	Attorney Docket Number	JAG 100	

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	:
Examinei's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Ť
/NWS/		FLEISCHER, et al., *Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians", Clin. Ther., 21:1725-31 (1999)	
		HENGGE, et al., J. Am. Acad. Dermatol, "Adverse effects of topical glucocorticosteroids", 54:1-15 (2006).	
	····	SHAFFER, et al., "Use of clotrimazole/betamethasone diproprionate by family physicians", Fam. Med., 32:561-5 (2000)	
\bigvee	:	SMITH, et al., "Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994", J. Am. Acad. Dermatol., 39:43-47 (1998)	
/NWS/		STERN, <i>J. Am. Acad. Dermatol.</i> , "The pattern of topical corticosteroid prescribing in the United States, 1989-1991", 35:183-6 (1996)	
			•••••
			•

processes and the second		***************************************		·	
Examiner's	/Nathan Schlightz/	•	Date Considered	0010010007	
Signature	/Naman Schilentz/	:	Lana Salvinia	f: 08/02/2007	
SiBilamia.			i l	00/02/2001	

Burden How Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on this amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to application.

¹ Unique citation designation number. See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant to place a check mark here if English language. Translation is attached.

Please type a	nhis sinn	l e l inside	this how

	PT0/5B/08A (10-98
Approved for use through 10/	31/89. OMB 0651-0031
Patent and Trademark Office, 11 9 DEDAG	THENT OF COMMERCE

					Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Papervio	ork Reduction Act of 1	895, no persons are a	required to respond to a collection of information unless it	contains e valid OMB control number	
. :	Substitute fo	or form 144	9A/PTO		
				C	complete if Known
			ION DISCLOSURE	Application Number	10/691,928
	SI	AIEWE	NT BY APPLICANT		
		(use as mar	y sheets as necessary)		0
· ·			•	Filing Date	October 23, 2003
	•			First Named Inventor	Jay A. Goldstein
1				Group Art Unit	1616
				Examiner Name	Nathan W. Schlientz
Sheet	1	of	1 .	Attorney Docket Number	JAG 100

	_	•		~~~~	U.S. PATENT DOCUM	ENTS	-
Examiner Initials*		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Number		Code ² known)			
			·····				

		<u> </u>					
	ļ			 			

					FOREIGN PATENT DOCUMEN	TS		
Examiner Initials*			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	⊤°		
		Office.3	Number⁴	Kind Code ⁶ (if known)				ŀ
NWS		EP	1 159 956		Johnson & Johnson Consumer	12-05-2001		
			4	-				
		-						
		LA						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Examiner's

Signature

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.